Literature DB >> 10155333

The role of pharmacoeconomics in health policy and management in Norway.

J Grund1, H Husbyn.   

Abstract

Mesh:

Year:  1995        PMID: 10155333     DOI: 10.2165/00019053-199507060-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  4 in total

1.  Norway's pivotal role in regulatory health economics and pharmaceutical cost containment--what can other countries learn?

Authors:  F Andersson
Journal:  Health Policy       Date:  1992-05       Impact factor: 2.980

2.  Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1992       Impact factor: 4.981

3.  Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.

Authors:  D Henry
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

Review 4.  Economic evaluation of pharmaceuticals: a European perspective.

Authors:  M Drummond; F Rutten; A Brenna; C G Pinto; B Horisberger; B Jönsson; C Le Pen; J Rovira; M G von der Schulenburg; H Sintonen
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

  4 in total
  2 in total

Review 1.  The societal value of pharmaceuticals. Balancing industrial and healthcare policy.

Authors:  J Grund
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

Review 2.  Pricing and reimbursement of pharmaceuticals. A new culture for the community pharmacist.

Authors:  E Moen; E L Toverud; J Grund; S Brinchmann
Journal:  Pharm World Sci       Date:  1998-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.